HUTCHMED announced an exclusive development and license agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate. HUTCHMED receives a US$110 million upfront payment and potential milestone payments up to US$1.295 billion, plus tiered royalties on net sales. GSK holds worldwide rights excluding Mainland China, Hong Kong, Macau, and Taiwan. Clinical development for colorectal, pancreatic, and lung cancer is expected to begin in H2 2026. HUTCHMED operates as a biopharmaceutical company focused on targeted therapies and immunotherapies for cancer.

HUTCHMED announced positive high-level results from the SANOVO Phase III trial in China for treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations and MET overexpression. The combination of ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to TAGRISSO alone in both high MET and intention-to-treat populations. Encouraging overall survival benefits were also observed as a secondary endpoint, with no new safety findings reported. The trial randomized 326 patients, building on prior successes from the SACHI and SAFFRON trials. HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies for cancer.

HUTCHMED (China) Limited received conditional approval from the China National Medical Products Administration for fanregratinib, marketed as ATLED®, to treat adult patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. Clinical data demonstrated an objective response rate of 42.5%, a median progression-free survival of 6.9 months, and a median overall survival of 16.6 months in the pivotal Phase II/IIIb trial. This regulatory milestone expands the company's commercial portfolio with a novel oral selective FGFR inhibitor targeting a high-unmet-need oncology indication. HUTCHMED is an innovative biopharmaceutical company focused on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases.

HUTCHMED (China) Limited reported total revenue of $278.3 million for the six months ended June 30, 2026, a flat change compared to $277.7 million in H1-25. Oncology/Immunology consolidated revenue grew 23% to $162.3 million, driven by strong China sales of ELUNATE® ($47.1 million) and SULANDA® ($18.4 million), alongside a $18.1 million milestone payment from Eli Lilly. Net income attributable to HUTCHMED was $15.9 million, down significantly from $455.0 million in H1-25 which included a $416.3 million gain on the divestment of 45% of Shanghai Hutchison Pharmaceuticals Limited. The company maintains a cash balance of $1.37 billion and reiterates full-year 2026 Oncology/Immunology revenue guidance of $330 million to $450 million. HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases.

HUTCHMED (China) Ltd. announced the NMPA approval for ORPATHYS® for the treatment of gastric cancer patients with MET amplification. HUTCHMED (China) Ltd. is a biopharmaceutical company focused on oncolytic therapy and & research and development.